Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins

被引:73
作者
Barnes, Kyra J. [1 ,2 ]
Rowland, Andrew [1 ,2 ]
Polasek, Thomas M. [1 ,2 ]
Miners, John O. [1 ,2 ]
机构
[1] Flinders Univ S Australia, Dept Clin Pharmacol, Adelaide, SA 5042, Australia
[2] Flinders Med Ctr, Adelaide, SA 5042, Australia
关键词
Uremic toxins; Renal impairment; Drug metabolism; Cytochromes P450; UDP-glucuronosyltransferase; STAGE RENAL-DISEASE; HUMAN-LIVER-MICROSOMES; MASS SPECTROMETRIC ANALYSIS; P-CRESOL; VIVO EXTRAPOLATION; QUANTITATIVE PREDICTION; HEPATIC-UPTAKE; RAT-LIVER; GLUCURONIDATION; FAILURE;
D O I
10.1007/s00228-014-1709-7
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
To investigate the potential inhibitory effects of uremic toxins on the major human hepatic drug-metabolising cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes in vitro. Benzyl alcohol, p-cresol, indoxyl sulfate, hippuric acid and a combination of the four uremic toxins were co-incubated with human liver microsomes and selective probe substrates for the major human drug-metabolising CYP and UGT enzymes. The percentage of enzyme inhibition was calculated by measuring the rates of probe metabolite formation in the absence and presence of the uremic toxins. Kinetics studies were conducted to evaluate the K (i) values and mechanism(s) of the inhibition of CYP2E1, CYP3A4, UGT1A1 and UGT1A9 by p-cresol. The individual uremic toxins inhibited CYP and UGT enzymes to a variable extent. p-Cresol was the most potent individual inhibitor, producing > 50 % inhibition of CYP2E1, CYP3A4, UGT1A1, UGT1A9 and UGT2B7 at a concentration of 100 mu M. The greatest inhibition was observed with UGT1A9. p-Cresol was shown to be an uncompetitive inhibitor of UGT1A9, with unbound K (i) values of 9.1 and 2.5 mu M in the absence and presence of bovine serum albumin (BSA), respectively. K (i) values for p-cresol inhibition of human liver microsomal CYP2E1, CYP3A4 and UGT1A1 ranged from 43 to 89 mu M. A combination of the four uremic toxins produced > 50 % decreases in the activities of CYP1A2, CYP2C9, CYP2E1, CYP3A4, UGT1A1, UGT1A9 and UGT2B7. Uremic toxins may contribute to decreases in drug hepatic clearance in individuals with kidney disease by inhibition of hepatic drug-metabolising enzymes.
引用
收藏
页码:1097 / 1106
页数:10
相关论文
共 70 条
[1]
EFFECTS OF AGING ON THE RENAL GLOMERULUS [J].
ANDERSON, S ;
BRENNER, BM .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (03) :435-442
[2]
BIANCHETTI G, 1976, Clinical Pharmacokinetics, V1, P373, DOI 10.2165/00003088-197601050-00004
[3]
In vitro-in vivo correlations for drugs eliminated by glucuronidation:: Investigations with the model substrate zidovudine [J].
Boase, S ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :493-503
[4]
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen [J].
Bowalgaha, K ;
Elliot, DJ ;
Mackenzie, PI ;
Knights, KM ;
Swedmark, S ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) :423-433
[5]
Free drug metabolic clearance in elderly people [J].
Butler, Jennifer M. ;
Begg, Evan J. .
CLINICAL PHARMACOKINETICS, 2008, 47 (05) :297-321
[6]
Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases [J].
Coughtrie, MWH ;
Sharp, S ;
Maxwell, K ;
Innes, NP .
CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 109 (1-3) :3-27
[7]
AGE CHANGES IN GLOMERULAR FILTRATION RATE, EFFECTIVE RENAL PLASMA FLOW, AND TUBULAR EXCRETORY CAPACITY IN ADULT MALES [J].
DAVIES, DF ;
SHOCK, NW .
JOURNAL OF CLINICAL INVESTIGATION, 1950, 29 (05) :496-507
[8]
Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum [J].
de Loor, H ;
Bammens, B ;
Evenepoel, P ;
De Preter, V ;
Verbeke, K .
CLINICAL CHEMISTRY, 2005, 51 (08) :1535-1538
[9]
A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure [J].
De Smet, R ;
David, F ;
Sandra, P ;
Van Kaer, J ;
Lesaffer, G ;
Dhondt, A ;
Lameire, N ;
Vanholder, R .
CLINICA CHIMICA ACTA, 1998, 278 (01) :1-21
[10]
GUANIDINO COMPOUNDS IN UREMIC DIALYZED PATIENTS [J].
DEDEYN, P ;
MARESCAU, B ;
LORNOY, W ;
BECAUS, I ;
LOWENTHAL, A .
CLINICA CHIMICA ACTA, 1986, 157 (02) :143-150